Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT06991127
Recruiting Not applicable

Clinical Investigation of MAIA Microperimeter Device: Mesopic Normative Database Collection

NCT06991127 · tracked via the Priya Life Science Australia tracker
Sponsor
Centervue SpA
Phase
Not applicable
Started
2025-04-23
Last updated
2025-05-25

Condition(s) studied

Healthy Eyes

Investigational drug(s) / intervention(s)

MAIA

MAIA: MAIA is an automatic microperimeter with fundus imaging capabilities that measures retinal sensitivity, fixation stability and locus of fixation, and allows the acquisition of confocal images of the retina, thanks to its confocal scanning imaging system which uses infrared and visible light.

Study summary

The purpose of this pre-market, multicentric cross-sectional study is to create a mesopic Normative Database for a new version of the MAIA device. Moreover, the study aims to evaluate MAIA safety and adverse events. These purposes will be achieved by collecting data of healthy subjects, who will undergo microperimetric examinations with the MAIA device during one single visit.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age: ≥18 years old; * Best Corrected Visual Acuity (BCVA): ≥ 0.8 Decimal (≥ 20/25 ft, ≤ +0.1 logMAR) at least in the study eye; * Equivalent spherical refraction between the range ≥ -6D and ≤ +6D; astigmatism within 2D (≤ 2D) at least in the study eye; * Intraocular Pressure (IOP) ≤ 21 mmHg in both eyes (Goldmann applanation tonometer); * Clinically normal appearance of the optic nerve head according to clinical judgement (no evidence of excavation, rim thinning, notching, disc hemorrhages, RNFL thinning) in both eyes. This is examined with Spectralis or Solix OCT; * Clinically normal appearance of the macula according to clinical judgement, in both eyes. This is examined with Spectralis or Solix OCT; * No ocular pathologies, trauma, surgeries (apart from uncomplicated cataract surgery or peripheral laser retinopexy performed at least 6 months before enrollment) in both eyes; * Absence of pathologies that can affect visual field in both eyes; * No use of drugs interfering with the correct execution of perimetry. Exclusion Criteria: * Glaucoma or glaucoma suspect diagnosis in either eye; * Presence or history of ocular hypertension (IOP ≥ 22 mmHg) in either eye; * Presence or history of disc hemorrhage in either eye; * Presence of amblyopia in either eye; * Nystagmus or poor fixation in either eye; * Previous laser or any ocular surgery, including uncomplicated cataract surgery performed within 6 months before enrollment in both eyes; * Any active infection of anterior or posterior segments in the study eye; * Subjects with significant ocular media opacities preventing acquisition of acceptable infrared (IR) fundus image quality in the study eye; * Evidence of diabetic retinopathy, diabetic macular edema, or other retinal disease in either eye; * Use of any drug that can interfere with the correct execution of MP or that would produce visual field loss; * Unable to tolerate ophthalmic imaging; * Claustrophobia; * Inability to provide informed consent.

Primary outcome measure(s)

  • To determine the reference normative values of retinal sensitivity for MAIA — 1 day
    The reference normative values will be determined by using a linear regression model for Mean Sensitivity (MS) as a function of age. The 5th and 10th percentile values will be derived for each age, and will serve as age-adjusted normative data against which compare the MS computed during each test with MAIA

Trial sites (3)

FacilityCityRegionStatus
The Eye Care Institute Fort Lauderdale Florida Not Yet Recruiting
UWA Eye Health Centre of Western Australia Perth Western Australia Not Yet Recruiting
Universitätsspital Basel, Augenklinik Basel Switzerland Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06991127 on ClinicalTrials.gov ↗ ← All trials in Australia